J
Joanie Salotti
Researcher at University of California, San Diego
Publications - 8
Citations - 1033
Joanie Salotti is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Fatty liver. The author has an hindex of 7, co-authored 8 publications receiving 839 citations.
Papers
More filters
Journal ArticleDOI
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
Rohit Loomba,Claude B. Sirlin,Brandon Ang,Ricki Bettencourt,Rashmi Jain,Joanie Salotti,Linda Soaft,Jonathan Hooker,Yuko Kono,Archana Bhatt,Laura Hernandez,Phirum Nguyen,Mazen Noureddin,William Haufe,Catherine A. Hooker,Meng Yin,Richard L. Ehman,Grace Y. Lin,Mark A. Valasek,David A. Brenner,Lisa Richards +20 more
TL;DR: This trial demonstrates the application of colocalization of MRI‐PDFF‐derived fat maps and magnetic resonance elastography‐derived stiffness maps of the liver before and after treatment to noninvasively assess treatment response in NASH.
Journal ArticleDOI
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study
Rohit Loomba,Nicholas J. Schork,Chi-Hua Chen,Ricki Bettencourt,Ana Bhatt,Brandon Ang,Phirum Nguyen,Carolyn Hernandez,Lisa Richards,Joanie Salotti,Steven C. Lin,Ekihiro Seki,Karen E. Nelson,Claude B. Sirlin,David A. Brenner +14 more
TL;DR: A cross-sectional analysis of a cohort of well-characterized twins residing in Southern California provides evidence that hepatic steatosis and hepatic fibrosis are heritable traits.
Journal ArticleDOI
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Jeffrey Cui,Len Philo,Phirum Nguyen,Heather Hofflich,Carolyn Hernandez,Ricki Bettencourt,Lisa Richards,Joanie Salotti,Archana Bhatt,Jonathan Hooker,William Haufe,Catherine A. Hooker,David A. Brenner,Claude B. Sirlin,Rohit Loomba +14 more
TL;DR: Sitagliptin was safe but not better than placebo in reducing liver fat in prediabetic or diabetic patients with NAFLD and demonstrates that non-invasive magnetic resonance imaging techniques can be used to assess treatment response in non-alcoholic fatty liver disease clinical trials.
Journal ArticleDOI
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis
Cyrielle Caussy,Meera Soni,Jeffrey Cui,Ricki Bettencourt,Nicholas J. Schork,Chi-Hua Chen,Mahdi Al Ikhwan,Shirin Bassirian,Sandra Cepin,Monica P. Gonzalez,Michel H. Mendler,Yuko Kono,Irine Vodkin,Kristin L. Mekeel,Jeffrey Haldorson,Alan W. Hemming,Barbara Andrews,Joanie Salotti,Lisa Richards,David A. Brenner,Claude B. Sirlin,Rohit Loomba +21 more
TL;DR: Using a well-phenotyped familial cohort, it is demonstrated that first-degree relatives of probands with NAFLD-cirrhosis have a 12 times higher risk of advanced fibrosis.
Journal ArticleDOI
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
Janki Patel,Ricki Bettencourt,Jeffrey Cui,Joanie Salotti,Jonathan Hooker,Archana Bhatt,Carolyn Hernandez,Phirum Nguyen,H. Aryafar,Mark A. Valasek,William Haufe,Catherine A. Hooker,Lisa Richards,Claude B. Sirlin,Rohit Loomba +14 more
TL;DR: It is demonstrated that a relative reduction of 29% in liver fat on MRI-PDFF is associated with a histologic response in NASH, and can be incorporated into designing future NASH clinical trials, especially those utilizing change in hepatic fat quantified by MRI- PDFF, as a treatment endpoint.